DOMA Perpetual Sends Letter To Board of Directors Of Pacira Biosciences To Immediately Accelerate And Increase Its Share Buyback Program To Enhance Return To Shareholders; Believes Pacira's Cash Balance Of $400M, Roughly 59% of Its Market Capitalization, Is Grossly Inefficient
Believes Pacira's Cash Balance of $400 million, Roughly 59% of its Market Capitalization, is Grossly Inefficient.
Emphasizes the Current Stock Price Offers an Extraordinary Opportunity to Create Meaningful Return for Shareholders
MIAMI, Sept. 25, 2024 /PRNewswire/ -- DOMA Perpetual Capital Management LLC today sent a letter to the Board of Directors of Pacira Biosciences (NYSE: PCRX) urging the Board to accelerate and increase its stock repurchase.
